ClinicalTrials.gg
CompletedNCT00511953Updated Jun 8, 2011

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

A Phase 2 interventional study of Gabapentin Extended Release tablets and Gabapentin in Hot Flashes, sponsored by Depomed. Completed at 8 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-08.

Sponsored by Depomed · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing gabapentin in Hot Flashes — none open to participants now, none under way, none of them phase 3. Gabapentin · Hot Flashes.

Planned enrollment
8th of 10
108 · median 160
Started
2007
the only one that year
Phase 2
3 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
4 of 11
Depomed

Among the 11 studies testing gabapentin in Hot Flashes, this one is the 8th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2, and was the 5th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 11 studies testing gabapentin in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

Where they have run

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing gabapentin in Hot Flashes as a file.
02

Study summary

Depomed's Gabapentin Extended Release is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women.

Read the detailed description

The primary objective of this clinical trial is to determine the optimal dose of Gabapentin ER in reducing the number and severity of hot flashes in postmenopausal women. Patients will be randomly assigned to Gabapentin ER or placebo, with a 1 in 4 chance of getting placebo. The total study investigational treatment duration after screening and baseline will be 13 weeks. The primary endpoint of the trial is to compare the number and severity of hot flashes during the investigational treatment compared to baseline. Sleep quality will also be evaluated.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • Hot flashes
  • Hot flushes
  • Postmenopausal symptoms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Generally healthy, women who seek treatment for hot flashes.
  2. Patients using hormone replacement therapy (HRT) must be willing to discontinue treatment.
  3. Patients must be experiencing at least 7 moderate to severe hot flashes per day.
  4. Patient must be willing to commit to 3 (optionally 4) overnight stays at the study site that will include frequent blood sampling.

Other inclusions apply.

Exclusion criteria

Exclusion Criteria:

  1. Patients with to gabapentin.
  2. Patients with severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss.
  3. Patients treated with estrogen pellets or injectable progestin drug therapy within 6 months.

Other exclusions apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Active comparator
    Gabapentin ER

    Active drug, Gabapentin extended release

    Drug: Gabapentin Extended Release tablets · Drug: Gabapentin

  • Placebo comparator
    Sugar Pill

    Comparator arm is Placebo

    Drug: Gabapentin Extended Release tablets · Drug: Gabapentin

Interventions

06

What researchers measure

Primary outcomes

  1. Frequency of moderate to severe hot flashes reported during the corresponding 24- hour blood samples collection period

    PD end points are considered as primary outcomes of this study

    Time frame: 24hrs

Secondary outcomes

  1. CGIC and PGIC evaluated prior to the start of 24- hour blood samples at week 6 and week 12 visits.

    Efficacy variables

    Time frame: 12 wks

07

Study locations

8 sites
  • Burbank, California, United States
  • DeLand, Florida, United States
  • Port Orange, Florida, United States
  • Shawnee, Kansas, United States
  • Baltimore, Maryland, United States
  • Hackensack, New Jersey, United States
  • Greenville, South Carolina, United States
  • San Antonio, Texas, United States
08

References and documents

Publications

  • Cowles VE, Gordi T, Hou SY. Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms. Clin Drug Investig. 2012 Sep 1;32(9):593-601. doi: 10.1007/BF03261914. PubMed 22775354 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Dec 2007 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2007
First posted
Aug 6, 2007
Start
Jun 2007
Primary completionActual
Dec 2007
CompletionActual
Feb 2008
Last update
Jun 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00511953
Lead sponsor
Depomed
First posted
Aug 6, 2007
Start date
Jun 2007
Primary completion
Dec 2007
Completion
Feb 2008
Last update
Jun 8, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion